English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background & Aims : Levofloxacin (LVFX) is a newly synthesized quinolone antibiotic, and although LVFX 500 mg once-daily has been reported to have good efficacy against with respiratory tract infections in the US and other countries, once-daily the regimen seldom been used in Japan. Methods : This randomized, parallel-group, open, multicenter clinical study was designed to compare a 7-day course of LVFX 300 mg once-daily with LVFX 100 mg three-times-daily in elderly patients with respiratory tract infections. Between February 2002 and March 2003, a total of 63 patients with significant respiratory tract infections were enrolled in this study. Results : Data were available for 49 patients. The clinical cure rate was 76.0% (19/25) in the LVFX 300 mg once-daily group and 83.3% (20/24) in the LVFX 100 mg three-times-daily group. The overall clinical cure rates and overall incidences of adverse reactions were similar in both groups. There was also no significant difference in compliance between the groups. Conclusions : LVFX 300 mg once-daily is as effective and safe as LVFX 100 mg three-times-daily in elderly patients with respiratory tract infections.

Levofloxacin 300 mg Once-daily Versus Levofloxacin 100 mg Three-times-daily in the Treatment of Respiratory Tract Infections in Elderly Patients